Pharmeasy Unlisted Share Price - IPO | Planify

PharmEasy IPO

What Is Pharmeasy • API Holding is India's leading digital healthcare platform, operating an integrated, end-to-end business that provides the solutions for healthcare needs of consumers across the critical stages. It's unified data platforms and supply chain capabilities etc enables it to service each of its stakeholder in the healthcare value chain.

• The company operates a consumer healthcare app called PharmEasy which enables on demand, home delivery of pharmaceutical products to the customers.

• The company has grown a lot since its inception and presently, in 2021, has 26 subsidiaries including Aknamed, Docon and Thyrocare.

• API Holdings is the holding entity for the PharmEasy group. API Holding was incorporated on March 31, 2019 and heads its operations from its office in Mumbai, Maharashtra.

Pharmeasy IPO Details • API Holdings Limited has filed its DRHP on 8th November 2021 and will be coming out with their IPO in this financial year.

• According to the DRHP the entire IPO only consists of a fresh issue, which means that none of the existing Pharmeasy shareholders of the company are selling their stake in the company. Their decision to not to cash out during the IPO indicates confidence among company’s investors about the growth potential of the company.

• The company may also consider a further issue of equity shares via a private placement of up to ₹1250 crore as mentioned in their DRHP.

Why Invest In Pharmeasy Share • The company has a first mover advantage in the industry due to which it has captured a wider market than any of it's peers. This first mover advantage has also helped pharmeasy to establish a strong brand name in the market.

• The revenue of the company has grown by a massive 220% in FY'21 over FY'20 which was majorly due to a huge surge in the demand for pharmaceuticals and healthcare products as a result of rise in pandemic.

• The company has recently entered into the diagnostic test provision services segment, which has allowed it to tap a larger market due to increased awareness on self care and precaution as a result of the widespread pandemic in the country.

Pharmeasy Revenue Growth • The company's revenue (pharmeasy Revenue Growth) has grown massively increasing from INR 737.4 Cr in FY'20 to INR 2360.6 Cr in FY'21.

This increase is mainly attributable to the massive rise in demand for pharmaceuticals due to the spread the of Covid-19 pandemic across the country.

THANKS FOR VISITING PLANIFY Visit for more Info Pharmeasy Share Price